Skip to main content
icon for Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?
Финансы·ABBV

Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?

icon for Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?
Финансы·ABBV

Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?

июл. 31

июл. 31

июл. 31

июл. 31

НОВОЕ
31 июл. 2026 г.
Polymarket

$768 Объем

Polymarket

$18 млрд

$65 Объем

28%

$19 млрд

$65 Объем

25%

$20 млрд

$67 Объем

12%

$21 млрд

$0 Объем

45%

$22 млрд

$571 Объем

23%

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".

The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.

If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".

If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".

If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.

The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.

Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Объем
$768
Дата окончания
31 июл. 2026 г.
Открытие рынка
Jul 18, 2026, 4:41 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".

The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.

If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".

If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".

If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.

The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.

Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Объем
$768
Дата окончания
31 июл. 2026 г.
Открытие рынка
Jul 18, 2026, 4:41 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Связанные

icon for Будет ли чистая глобальная выручка Rinvoq AbbVie во 2 квартале выше $2,3 млрд?

Будет ли чистая глобальная выручка Rinvoq AbbVie во 2 квартале выше $2,3 млрд?

80%
Да
icon for Будут ли доходы от рейтингов S&P Global (SPGI) за 2-й квартал превышать $12,5 млрд?

Будут ли доходы от рейтингов S&P Global (SPGI) за 2-й квартал превышать $12,5 млрд?

4%
Да
icon for Will Verizon (VZ) Q2 total operating revenue be above $34.5B?

Will Verizon (VZ) Q2 total operating revenue be above $34.5B?

86%

Не доверяй внешним ссылкам.

Часто задаваемые вопросы

«Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?» — это рынок прогнозов на Polymarket с 5 возможными исходами, где трейдеры покупают и продают акции на основе своих прогнозов. Текущий лидирующий исход — «$21 млрд» с 45%, за ним следует «$18 млрд» с 28%. Цены отражают вероятности сообщества в реальном времени. Например, акция по цене 45¢ означает, что рынок коллективно оценивает вероятность этого исхода в 45%. Эти коэффициенты постоянно меняются. Акции правильного исхода можно обменять на $1 каждую при разрешении рынка.

«Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?» — недавно созданный рынок на Polymarket, запущен Jul 18, 2026. Как ранний рынок, это твоя возможность быть среди первых трейдеров, устанавливающих коэффициенты и формирующих начальные ценовые сигналы. Ты также можешь добавить эту страницу в закладки, чтобы следить за объёмом и активностью торгов.

Чтобы торговать на «Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?», просмотри 5 доступных исходов на этой странице. Каждый исход показывает текущую цену, представляющую подразумеваемую вероятность рынка. Чтобы занять позицию, выбери исход, который считаешь наиболее вероятным, выбери «Да» для торговли в его пользу или «Нет» для торговли против, введи сумму и нажми «Торговать». Если твой выбранный исход окажется верным, твои акции «Да» принесут $1 каждая. Если нет — $0. Ты также можешь продать акции до разрешения.

Текущий фаворит для «Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?» — «$21 млрд» с 45%, что означает, что рынок оценивает вероятность этого исхода в 45%. Следующий ближайший исход — «$18 млрд» с 28%. Эти коэффициенты обновляются в реальном времени по мере покупки и продажи акций. Заходи чаще или добавь страницу в закладки.

Правила разрешения «Будет ли чистая выручка AbbVie Q2 Global Skyrizi выше __?» точно определяют, что должно произойти, чтобы каждый исход был объявлен победителем, включая официальные источники данных, используемые для определения результата. Ты можешь просмотреть полные критерии разрешения в разделе «Правила» на этой странице над комментариями. Мы рекомендуем внимательно прочитать правила перед торговлей, так как они определяют точные условия, особые случаи и источники.